Founded in 2022, Profluent Bio has built an AI-first platform that applies large-scale language models to de novo protein design. The company’s Protein Atlas now contains more than 115 billion unique proteins, giving it what it claims is the world’s largest protein data resource. Its technology has already produced OpenCRISPR-1, an open-source gene editor used by thousands of commercial and academic groups, and it maintains commercial partnerships with Revvity, Corteva Agrisciences, The Rett Syndrome Research Trust and Integrated DNA Technologies. Profluent was the first to show that large language models can generate functional proteins (Nature Biotech, 2023) and later designed the first AI-created CRISPR system from scratch (Nature, 2025). With new funding the company is expanding beyond genome editors into antibodies, antigens, enzymes and other biologic formats, aiming to become the partner of choice for protein design across multi-trillion-dollar markets. To date, the Emeryville-based company has raised $150 million, including the latest $106 million round to accelerate product development and commercial scale.

Total raised

$141M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2025